Metabolites,
Год журнала:
2025,
Номер
15(2), С. 127 - 127
Опубликована: Фев. 13, 2025
Numerous
recent
studies
have
suggested
that
the
composition
of
intestinal
microbiota
can
trigger
metabolic
disorders,
such
as
diabetes,
prediabetes,
obesity,
syndrome,
sarcopenia,
dyslipidemia,
hyperhomocysteinemia,
and
non-alcoholic
fatty
liver
disease.
Since
then,
considerable
effort
has
been
made
to
understand
link
between
well
role
probiotics
in
modulation
microbiota.
The
aim
this
review
was
summarize
reviews
individual
articles
on
state
art
regarding
ideal
therapy
with
prebiotics
order
obtain
reversion
dysbiosis
(alteration
microbiota)
eubiosis
during
diseases,
diseases.
This
includes
245
eligible
studies.
In
conclusion,
a
condition
dysbiosis,
or
general,
alteration
microbiota,
could
be
implicated
development
disorders
through
different
mechanisms,
mainly
linked
release
pro-inflammatory
factors.
Several
already
demonstrated
potential
using
treatment
condition,
detecting
significant
improvements
specific
symptoms
These
findings
reinforce
hypothesis
lead
generalized
inflammatory
picture
negative
consequences
organs
systems.
Moreover,
confirms
beneficial
effects
diseases
are
promising,
but
more
research
is
needed
determine
optimal
probiotic
strains,
doses,
administration
forms
for
conditions.
Current Obesity Reports,
Год журнала:
2024,
Номер
13(3), С. 510 - 531
Опубликована: Май 29, 2024
The
prevalence
of
non-alcoholic
fatty
liver
disease
(NAFLD)
is
rapidly
increasing
worldwide,
making
it
the
leading
cause
related
morbidity
and
mortality.
Currently,
biopsy
gold
standard
for
assessing
individuals
with
steatohepatitis
fibrosis.
However,
its
invasiveness,
sampling
variability,
impracticality
large-scale
screening
has
driven
search
non-invasive
methods
early
diagnosis
staging.
In
this
review,
we
comprehensively
summarise
evidence
on
diagnostic
performance
limitations
existing
serum
biomarkers
scores
in
evaluation
steatosis,
steatohepatitis,
Metabolites,
Год журнала:
2024,
Номер
14(7), С. 366 - 366
Опубликована: Июнь 28, 2024
Nonalcoholic
fatty
liver
disease
(NAFLD)
poses
an
emerging
threat
topublic
health.
steatohepatitis
(NASH)
is
reported
to
be
the
most
rapidly
rising
cause
of
hepatocellular
carcinoma
in
western
world.
Recently,
a
new
term
has
been
proposed:
metabolic
dysfunction-associated
steatotic
(MASLD).
The
introduction
this
terminology
sparked
debate
about
interchangeability
these
terms.
pathogenesis
NAFLD/MASLD
thought
multifactorial,
involving
both
genetic
and
environmental
factors.
Among
factors,
alterations
gut
microbiota
dysbiosis
have
recently
garnered
significant
attention.
In
context,
review
will
further
discuss
gut-liver
axis,
which
refers
bidirectional
interaction
between
human
liver.
Additionally,
therapeutic
potential
probiotics,
particularly
next-generation
probiotics
genetically
engineered
bacteria,
explored.
Moreover,
role
prebiotics,
synbiotics,
postbiotics,
phages
as
well
fecal
transplantation
analyzed.
Particularly
for
lean
patients
with
NAFLD/MASLD,
who
limited
treatment
options,
approaches
that
modify
diversity
composition
may
hold
promise.
However,
due
ongoing
safety
concerns
modulate
microbiota,
large-scale
studies
are
necessary
better
assess
their
efficacy
treating
NAFLD/MASLD.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(7), С. 3746 - 3746
Опубликована: Март 27, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
influenced
by
a
variety
of
factors,
including
environmental
and
genetic
factors.
The
most
significant
outcome
the
alteration
free
fatty
acid
triglyceride
metabolism.
Lipotoxicity,
impaired
autophagy,
chronic
inflammation,
oxidative
stress,
as
well
coexisting
insulin
resistance,
obesity,
changes
in
composition
gut
microbiota,
are
also
considered
crucial
factors
pathogenesis
MASLD.
Resveratrol
polyphenolic
compound
that
belongs
to
stilbene
subgroup.
This
review
summarises
available
information
on
therapeutic
effects
resveratrol
against
has
demonstrated
promising
antisteatotic,
antioxidant,
anti-inflammatory
activities
cells
vitro
animal
studies.
been
associated
with
inhibiting
NF-κB
pathway,
activating
SIRT-1
AMPK
pathways,
normalizing
intestinal
microbiome,
alleviating
inflammation.
However,
clinical
studies
have
yielded
inconclusive
results
regarding
efficacy
hepatic
steatosis
or
reducing
any
parameters
found
MASLD
human
patients.
lack
homogeneity
between
studies,
low
bioavailability
resveratrol,
population
variability
when
compared
models
could
be
reasons
for
this.
Nutrients,
Год журнала:
2024,
Номер
16(14), С. 2220 - 2220
Опубликована: Июль 11, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
common
long-lasting
that
affects
millions
of
people
around
the
world.
It
best
identified
with
hepatic
fat
build-up
ultimately
leads
to
inflammation
and
damage.
The
classification
nomenclature
NAFLD
have
long
been
controversial
topic,
until
2020
when
group
international
experts
recommended
substituting
MAFLD
(metabolic
dysfunction-associated
FLD).
was
then
terminologically
complemented
in
2023
by
altering
it
MASLD,
i.e.,
metabolic
steatotic
(MASLD).
Both
MASLD
terminologies
comprise
element
disorder,
as
they
offer
diagnostic
benchmarks
are
embedded
risk
factors
underlie
disease.
(as
multisystemic
disease)
provides
comprehensive
definition
includes
larger
population
patients
who
at
morbidity
mortality,
well
adverse
cardiovascular
diabetes
outcomes.
highlights
risks
lean
or
normal
weight
individuals,
factor
has
not
accentuated
discussed
previous
guidelines.
Novel
antihyperglycemic
agents,
anti-hyperlipidemic
drugs,
lifestyle
modifications,
nutritional
interventions,
exercise
therapies
extensively
studied
MASLD.
Nutrition
plays
vital
role
managing
both
conditions,
where
centralizing
on
diet
rich
whole
vegetables,
fruits,
foods,
healthy
fats,
proteins,
specific
nutrients
(e.g.,
omega-3
acids
fibers)
can
improve
insulin
resistance
reduce
inflammation.
Thus,
essential
understand
nutrition
these
conditions
work
develop
an
individualized
plan
for
optimal
health.
This
review
discusses
prevention
strategies
NAFLD/MAFLD/MASLD
management,
particular
attention
correction.
Signal Transduction and Targeted Therapy,
Год журнала:
2025,
Номер
10(1)
Опубликована: Фев. 4, 2025
Abstract
As
a
highly
complex
organ
with
digestive,
endocrine,
and
immune-regulatory
functions,
the
liver
is
pivotal
in
maintaining
physiological
homeostasis
through
its
roles
metabolism,
detoxification,
immune
response.
Various
factors
including
viruses,
alcohol,
metabolites,
toxins,
other
pathogenic
agents
can
compromise
function,
leading
to
acute
or
chronic
injury
that
may
progress
end-stage
diseases.
While
sharing
common
features,
diseases
exhibit
distinct
pathophysiological,
clinical,
therapeutic
profiles.
Currently,
contribute
approximately
2
million
deaths
globally
each
year,
imposing
significant
economic
social
burdens
worldwide.
However,
there
no
cure
for
many
kinds
of
diseases,
partly
due
lack
thorough
understanding
development
these
Therefore,
this
review
provides
comprehensive
examination
epidemiology
characteristics
covering
spectrum
from
conditions
manifestations.
We
also
highlight
multifaceted
mechanisms
underlying
initiation
progression
spanning
molecular
cellular
levels
networks.
Additionally,
offers
updates
on
innovative
diagnostic
techniques,
current
treatments,
potential
targets
presently
under
clinical
evaluation.
Recent
advances
pathogenesis
hold
critical
implications
translational
value
novel
strategies.
Cardiovascular Diabetology,
Год журнала:
2025,
Номер
24(1)
Опубликована: Янв. 13, 2025
Triglyceride-glucose
(TyG)
related
indices,
which
serve
as
simple
markers
for
insulin
resistance,
have
been
closely
linked
to
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
cardiovascular
(CVD),
and
mortality.
However,
the
prognostic
utility
of
TyG-related
indices
in
predicting
risk
CVD
mortality
among
patients
with
MASLD
remains
unclear.
Data
97,331
patients,
a
median
age
58.0
years
free
at
baseline,
were
obtained
from
UK
Biobank.
The
TyG
index,
along
its
combination
adiposity
parameters
(i.e.
body
mass
index
[BMI],
waist
circumference
[WC],
waist-to-height
ratio
[WHtR]),
calculated.
Cox
proportional
hazards
models
restricted
cubic
spline
(RCS)
performed
evaluate
associations
between
overall
CVD,
coronary
heart
(CHD),
stroke,
all-cause
mortality,
Additionally,
Harrell's
C-index,
net
reclassification
(NRI),
integrated
discrimination
improvement
(IDI)
used
assess
predictive
performance
these
indices.
Over
follow-up
13.56
years,
we
identified
13,256
cases
10,980
CHD,
2,926
8,809
1,796
Compared
lowest
quartile
participants
high
had
significantly
increased
incident
Specifically,
hazard
ratios
occurring
fourth
versus
first
quartiles
1.19
(95%
confidence
interval:
1.13-1.25)
TyG,
1.35
(1.28-1.42)
TyG-BMI,
1.33
(1.26-1.40)
TyG-WC,
1.39
(1.32-1.46)
TyG-WHtR.
RCS
analyses
indicated
nonlinear
association
outcomes
(all
P
values
nonlinearity
<
0.05),
whereas
there
exhibited
linear
trends
TyG-WHtR
>
0.05,
except
TyG-WC
stroke).
Furthermore,
demonstrated
higher
NRI,
IDI
patients.
especially
TyG-WHtR,
significant
individuals
MASLD.
may
effective
surrogate
predictors
Current Issues in Molecular Biology,
Год журнала:
2023,
Номер
45(6), С. 4544 - 4556
Опубликована: Май 24, 2023
Glucagon-like
peptide
1
receptor
agonists
(GLP-1RAs)
have
been
shown
to
improve
glucose
and
lipid
homeostasis,
promote
weight
loss,
reduce
cardiovascular
risk
factors.
They
are
a
promising
therapeutic
option
for
non-alcoholic
fatty
liver
disease
(NAFLD),
the
most
common
disease,
associated
with
T2DM,
obesity,
metabolic
syndrome.
GLP-1RAs
approved
treatment
of
T2DM
but
not
NAFLD.
Most
recent
clinical
trials
suggested
importance
early
pharmacologic
intervention
in
alleviating
limiting
NAFLD,
as
well
highlighting
relative
scarcity
vitro
studies
on
semaglutide,
indicating
need
further
research.
However,
extra-hepatic
factors
contribute
GLP-1RA
results
vivo
studies.
Cell
culture
models
NAFLD
can
be
helpful
eliminating
extrahepatic
effects
alleviation
hepatic
steatosis,
modulation
metabolism
pathways,
reduction
inflammation,
prevention
progression
severe
conditions.
In
this
review
article,
we
discuss
role
GLP-1
using
human
hepatocyte
models.